Search

Your search keyword '"Steg, Philippe G."' showing total 259 results

Search Constraints

Start Over You searched for: Author "Steg, Philippe G." Remove constraint Author: "Steg, Philippe G."
259 results on '"Steg, Philippe G."'

Search Results

1. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

2. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

6. Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

8. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial

10. Abstract 11958: Incidence and Predictors of In-Hospital Complications After Myocardial Infraction in Contemporary Clinical Practice: Findings From the FRENCHIE Myocardial Infarction Cohort

11. Abstract 13699: Bivalirudin versus Heparin in Patients With NSTEMI Undergoing PCI: Individual-Patient-Data Pooled Analysis of the 5 Major Randomized Trials

12. Abstract 13639: Bivalirudin versus Heparin in Patients With STEMI Undergoing PCI: Individual-Patient-Data Pooled Analysis of the 6 Major Randomized Trials

14. Abstract 10470: Projected Lifetime Benefits of Alirocumab in Patients After Acute Coronary Syndrome

17. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

18. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative

19. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials

20. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry

22. Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial

24. Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG

26. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease

27. Geographic Differences in Patients With Acute Myocardial Infarction in The PARADISE‐MI Trial

28. Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial

29. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials

30. Abstract 9330: Machine Learning Can Enable the Automation of Clinical Endpoint Adjudication

31. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

32. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials

33. EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study

34. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry

35. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction

37. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI):design and baseline characteristics

38. P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary intervention

39. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

40. Abstract 57: Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT

41. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the breathing not properly multinational study

42. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials

43. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

44. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines

45. 403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial

46. 4-LB: Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES

48. Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27–28 September 2007

49. †Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

Catalog

Books, media, physical & digital resources